drugset
drugset / Trial / NCT00582504

Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine

NCT00582504 ↗

Phase 2 Unknown 500 enrolled U.S. Army Medical Research and Development Command
NaSingle-groupOpen-labelPrevention

Summary

This study is designed to determine safety of and immune response to Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).

Timeline

Start
2007-09
Primary completion
2021-12
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VEE TC-83 Vaccine 0.5 ml Subcutaneous

Indications

Venezuelan equine encephalitis